Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine Sulfate

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

Concomitant use can cause hypertensive crisis with potential outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure. Do not use concomitantly or within 14 days after discontinuing MAOI.

Concomitant use can cause hypertensive crisis with potentially fatal outcomes including death, stroke, myocardial infarction, aortic dissection, and renal failure. Do not use concomitantly or within 14 days after discontinuing MAOI.

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

Concomitant use can cause hypertensive crisis with potentially fatal outcomes including death, stroke, myocardial infarction, and aortic dissection. Do not use concomitantly or within 14 days of MAOI discontinuation.

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

Gastrointestinal alkalinizing agent that increases amphetamine blood levels and potentiates action. Co-administration should be avoided.

MAOI that potentiates amphetamine effects; concomitant use can cause hypertensive crisis with potentially fatal outcomes including stroke, MI, aortic dissection.

Urinary alkalinizing agent that increases blood levels and potentiates amphetamine action. Co-administration should be avoided.

Increase blood levels and potentiate the action of amphetamine. Co-administration should be avoided.

Serotonergic drug that increases risk of serotonin syndrome when combined with amphetamines. Initiate with lower doses and monitor for serotonin syndrome signs.

Tricyclic antidepressant may enhance activity causing striking sustained increases in d-amphetamine concentration and potentiated cardiovascular effects. Monitor frequently and adjust therapy as needed.

Serotonergic drug that increases risk of serotonin syndrome when combined with amphetamines. Initiate with lower doses and monitor for serotonin syndrome signs.

CYP2D6 inhibitor and serotonergic drug that increases amphetamine exposure and risk of serotonin syndrome. Initiate with lower doses and monitor for serotonin syndrome.

Serotonergic drug that increases risk of serotonin syndrome when combined with amphetamines. Initiate with lower doses and monitor for serotonin syndrome signs.

There has been one report of severe congenital bony deformity, tracheo-esophageal fistula, and anal atresia (vater association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy.

Opioid whose effects may be potentiated by amphetamines, with serotonergic properties increasing serotonin syndrome risk.

Effects may be potentiated by amphetamines.

CYP2D6 inhibitor and serotonergic drug that increases amphetamine exposure and risk of serotonin syndrome. Initiate with lower doses and monitor for serotonin syndrome.

Tricyclic antidepressant may enhance activity causing striking sustained increases in d-amphetamine concentration and potentiated cardiovascular effects. Monitor frequently and adjust therapy as needed.

CYP2D6 inhibitor that increases amphetamine exposure and risk of serotonin syndrome. Initiate with lower doses and monitor for serotonin syndrome.

CYP2D6 inhibitor that increases amphetamine exposure and risk of serotonin syndrome. Initiate with lower doses and monitor for serotonin syndrome.

Concomitant use increases the risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation or dosage increase.

Serotonergic drug that increases risk of serotonin syndrome when combined with amphetamines. Initiate with lower doses and monitor for serotonin syndrome signs.

Some thiazides are urinary alkalinizing agents that increase amphetamine blood levels and potentiate action. Co-administration should be avoided.

Serotonergic drug that increases risk of serotonin syndrome when combined with amphetamines. Initiate with lower doses and monitor for serotonin syndrome signs.

Concomitant use increases the risk of serotonin syndrome. Monitor for signs and symptoms, particularly during initiation or dosage increase.

Serotonergic drug that increases risk of serotonin syndrome when combined with amphetamines. Initiate with lower doses and monitor for serotonin syndrome signs.

Lower blood levels and efficacy of amphetamines. Dose adjustment based on clinical response may be needed.

Adrenergic blockers are inhibited by amphetamines, potentially reducing their therapeutic effect.

Urinary acidifying agent that lowers blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Acidifying agent that lowers blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Amphetamines may reduce the effects of this drug. Monitor for reduced efficacy.

Potential change in pharmacokinetic profile and exposure may occur. Monitor for changes in clinical effect.

Acidifying agent that lowers blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Acidifying agent that lowers blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Urinary acidifying agent that lowers blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Amphetamines may reduce the effects of this drug. Monitor for reduced efficacy.

Amphetamines may reduce the effects of this drug. Monitor for reduced efficacy.

Acidifying agent that lowers blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Urinary acidifying agent that lowers blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Increase blood levels and potentiate the action of amphetamine.

Effects of veratrum alkaloids may be reduced by amphetamines.

An example of a proton pump inhibitor is omeprazole. An example of a proton pump inhibitor is omeprazole.